Tango reports Q3 loss $29.2M; TNG462 shows durable activity; PRMT5 program advanced

Tango Therapeutics, Inc.

2024-Q3 EPS reported -$0.85 revenue$37,952,000

TNG462 demonstrated clinical activity across multiple tumor types; 43% ORR in cholangiocarcinoma (n=7); median time on treatment 24 weeks and increasing.
Multiple TNG462 combos planned 1H 2025 with RAS(ON) inhibitors (Revolution Medicines), osimertinib, and pembrolizumab.
TNG908 enrollment stopped due to insufficient CNS exposure in glioblastoma; next-gen brain-penetrant TNG456 enters phase 1/2 1H 2025.
Cash $293M as of Sept 30, 2024; cash runway into 3Q 2026; Q3 net loss $29.2M ($0.27/shr) vs $22.3M ($0.23/shr) year ago.
Maeve Waldron-Lynch, M.D. joins as SVP Head of Clinical Development, bringing late-stage oncology regulatory experience.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.